Emergent BioSolutions Inc. has received approval from the U.S. Food and Drug Administration (FDA) for its supplemental New Drug Application (sNDA) regarding new multipack configurations of over-the-counter (OTC) NARCAN® Nasal Spray. The approval expands the NARCAN® Nasal Spray product lineup to include 6-count and 24-count multipack options, intended to support partners distributing higher volumes of naloxone. These new formats are designed to enhance distribution efficiency and flexibility for community programs and organizations involved in large-scale or multi-site opioid overdose response efforts. The new multipacks will be available for purchase through NARCANDirect®, Emergent’s proprietary ordering platform, and will complement existing product formats.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Emergent BioSolutions Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9654230-en) on February 12, 2026, and is solely responsible for the information contained therein.